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The inflammatory functions of the cytokine tumor
necrosis factor (TNF) rely on its ability to induce cyto-
kine production and to induce cell death. Caspase-
dependent and caspase-independent pathways—
apoptosis and necroptosis, respectively—regulate
immunogenicity by the release of distinct sets of
cellular proteins. To obtain an unbiased, systems-
level understanding of this important process, we
here applied mass spectrometry-based proteomics
to dissect protein release during apoptosis and nec-
roptosis. We report hundreds of proteins released
from human myeloid cells in time course experi-
ments. Both cell death types induce receptor shed-
ding, but only apoptotic cells released nucleosome
components. Conversely, necroptotic cells release
lysosomal components by activating lysosomal
exocytosis at early stages of necroptosis-induced
membrane permeabilization and show reduced
release of conventionally secreted cytokines.INTRODUCTION
Tumor necrosis factor (TNF) is a major contributor to many in-
flammatory diseases, including psoriasis, rheumatoid arthritis,
and inflammatory bowel disease (Bradley, 2008). This has
initially been linked to TNF-induced production of various cy-
tokines via nuclear factor kB (NF-kB) and mitogen-activated
protein kinase (MAPK) pathway activation (Bradley, 2008).
Subsequent reports, however, revealed a major role of TNF-
induced cell death in inflammatory diseases (Rock and
Kono, 2008). Binding of TNF to its receptor TNF-R1 activates
the NF-kB and MAPK pathways, leading to cytokine produc-
tion. Cellular inhibitor of apoptosis 1 and 2 (cIAP1 and
cIAP2) regulate the activation of these pathways via their E3
ubiquitin ligase activity toward receptor-interacting serine/
threonine-protein kinase 1 (RIPK1) (Bertrand et al., 2008). Inhi-
bition of cIAPs using small molecules called Smac mimetics
(SMs) results in decreased NF-kB signaling and caspase-8
activation (Arslan and Scheidereit, 2011; Vince et al., 2007;1260 Cell Reports 30, 1260–1270, January 28, 2020 ª 2019 The Auth
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downstream caspases and initiates the apoptotic process,
which involves nuclear fragmentation, blebbing, and cell
shrinkage (Elmore, 2007). During the early stages of apoptosis,
phosphatidylserine is exposed on the cell surface, which is
recognized by macrophages that engulf dying cells (Fadok
et al., 1992). Although released histones have been described
to activate Toll-like receptors and induce cytokine production,
apoptosis is conceptually considered an immunological
silent death (Elliott and Ravichandran, 2010).
Caspase inhibition prevents apoptosis, but in many cell
types it triggers an alternative cell death pathway termed nec-
roptosis (Vercammen et al., 1998). Upon TNF signaling, cas-
pase-8 regulates necroptosis by cleaving RIPK1 (Oberst
et al., 2011; Pop et al., 2011). Caspase-8 inhibition leads to
autophosphorylation and activation of RIPK1 and RIPK3.
Active RIPK3 phosphorylates and activates the pseudokinase
mixed lineage kinase domain-like protein (MLKL) (Murphy
et al., 2013; Wang et al., 2014; Tanzer et al., 2017). Active
MLKL translocates to the plasma membrane to induce mem-
brane rupture (Hildebrand et al., 2014; Sun et al., 2012). Nec-
roptosis is primarily thought of as an immunologically reactive
process, because of its fast kinetics, the release of damage-
associated molecular patterns (DAMPs) such as high mobility
group box 1 protein (HMGB1) and ATP, as well as reduced
macrophage engulfment (Kaczmarek et al., 2013).
Different modes of cell death can lead to significantly
different physiological outcomes through the release of
distinct molecules. For example, it was recently reported
that necroptotic cell death in contrast to apoptotic cell death
can drive a systemic immune response, leading to tumor
regression (Snyder et al., 2019). The same group showed
that cytokine mRNA translation continues at the endoplasmic
reticulum (ER) during necroptosis even after plasma mem-
brane rupture (Orozco et al., 2019). Another study reported
that the cell death-dependent cytokine microenvironment
determines the lineage commitment and thereby the harmful-
ness of hepatic cancer (Seehawer et al., 2018). Other studies
compared the ability of cytokine and chemokine release by
apoptotic and necroptotic cells (Kearney et al., 2015; Zhu
et al., 2018). However, whereas Kearney et al. (2015) observed
a decrease in cytokines released by necroptotic cells, Zhu
et al. (2018) reported an activation of pro-inflammatoryors.
creativecommons.org/licenses/by-nc-nd/4.0/).
cytokine gene expression instead. Together these studies
underline the different properties of apoptotic and necroptotic
cells on their surrounding microenvironment, which would now
make it attractive to systematically investigate the released
cellular contents.
Mass spectrometry-based proteomics has matured remark-
ably in recent years and now provides a comprehensive
discovery tool to address diverse biological questions (Aeber-
sold and Mann, 2016; Larance and Lamond, 2015). Here we
set out to identify proteins released by apoptotic versus
necroptotic cell death programs using a proteomics strategy
we developed recently for the sensitive detection of secreted
proteins (Meissner et al., 2013; Frauenstein and Meissner,
2018).
We induced TNF-mediated apoptosis and necroptosis in a
lymphoma cell line and human primary macrophages. Proteo-
mic analysis of supernatants and of enriched extracellular ves-
icles shed light on processes regulated during necroptosis and
apoptosis and the cell death type-specific release of
cytokines.
RESULTS
Differential Release of Proteins in Cells Undergoing
TNF-Induced Apoptosis and Necroptosis
To define the inflammatory potential of apoptosis and necropto-
sis on a global scale, we set out to identify proteins released by
cells undergoing TNF-mediated apoptosis or necroptosis. We
induced both forms of cell death in the histiocytic lymphoma
cell line U937 and in human primary macrophages, two cell
types frequently used to investigate these cell death pathways
(Tanzer et al., 2015; McComb et al., 2012) (Figure 1A).
Apoptosis was triggered by TNF and the SM birinapant, while
the further addition of the caspase inhibitor IDUN-6556 (IDN-
6556) led to necroptosis. Both processes showed similar ki-
netics when comparing caspase cleavage (Figure 1B), a hall-
mark of apoptosis, with phosphorylation of MLKL (Figure 1C),
a hallmark of necroptosis. During necroptosis, activated
MLKL translocates to the plasma membrane and leads to im-
mediate membrane permeabilization and propidium iodide
intake (Hildebrand et al., 2014), whereas apoptotic cells retain
plasma membrane integrity until the later stages when second-
ary necrosis occurs (Figure 1D; Figure S1A). A recent report
showed that active caspase-8 can cleave gasdermin-D, a
pore-forming protein that induces plasma membrane rupture
during pyroptosis (Orning et al., 2018). We cannot exclude
processing of gasdermin-D at later time points of apoptosis.
Nevertheless, the slow kinetics and reduced level of propidium
iodide intake (Figure 1D) and the delayed release of HMGB1
(Figures S2B and S2C) (a prominent marker of necroptosis
and pyroptosis; Kaczmarek et al., 2013) are strong indications
against a potential involvement of pyroptosis upon TNF and
SM stimulation, at least before secondary necrosis.
To analyze proteins released by apoptotic and necroptotic
cells, supernatants were harvested and digested, and the
resulting peptides were directly analyzed by single-run liquid
chromatography mass spectrometry (LC-MS/MS) coupled to
high-resolution mass spectrometry on the quadrupole Orbitrapanalyzer (STAR Methods; Figure 1A). Label-free quantification
of the MS data and statistical analysis were performed using
MaxQuant and Perseus (Cox and Mann, 2008; Tyanova et al.,
2016). Overall, 3,507 proteins were identified from U937 super-
natants, with an average of 2,058 protein groups per sample
(Figure 1E). Principal-component analysis revealed partial stim-
ulation and time-dependent separation of samples (Figures
S1B and S1C). Necroptotic supernatants from later time points,
when membrane permeabilization occurred, separated from the
rest of the samples (Figures S1B and S1C). Consistently, the
levels of hundreds of proteins were significantly changed in the
supernatants of necroptotic cells, compared with control sam-
ples (Figure 1F). In contrast, this was the case for only 34 proteins
in apoptosis. However, at a later time point apoptotic cells,
which undergo secondary necrosis, also significantly released
several hundreds of proteins (Figure S1D). The fold changes
of all proteins measured across seven apoptotic and four nec-
roptotic time points compared with respective controls are
provided in Table S1. When we analyzed the proteome of the
dying cells, the most apparent variation in protein levels
occurred in necroptotic cells, including a reduction in cytosolic
proteins, and an increase in mitochondrial proteins and proteins
located at the ER (Figure S1E).
The Release of Conventionally Secreted Cytokines Is
Significantly Reduced in Necroptotic Cells
TNF induces the production of a wide range of cytokines
required to fight infection, and we were particularly interested
in the effect of TNF-induced cell death on their release. CCL2
and IL8 were most strongly induced through TNF stimulation
in U937 cells (Figures 2A and 2B), looking at all cytokines
(retrieved from the keyword annotation ‘‘Cytokines’’; STAR
Methods). At later time points, levels of CCL2 and IL8 were
diminished in supernatants of apoptotic cells, but this was
not statistically significant. However, we observed a significant
downregulation for both cytokines during necroptosis
compared with TNF-only treatment. To confirm our mass
spectrometry results, we used enzyme-linked immunosorbent
assay (ELISA) to measure levels of CCL2 and HMGB1 in su-
pernatants, which showed a similar trend (Figures S2A–S2C).
CCL2 and IL8 contain an N-terminal signal peptide and are
therefore part of the keyword annotation ‘‘Signal’’ (hereafter
referred to as signal proteins). The signal peptide mediates
conventional secretion through the ER-Golgi secretory
pathway. Other conventionally secreted cytokines were also
downregulated at later stages of necroptosis in U937 cells
(Figure S2D) and primary macrophages (Figures 2C and 2D;
Figure S2E). Levels of most non-conventionally released
cytokines were primarily unaffected or increased in necrop-
totic supernatants because of membrane permeabilization
(Figure S2F). AIMP-1 levels, for example, were enriched in a
minor but significant way in necroptotic supernatants
(Figure S2F).
We examined the release of all conventionally released
proteins to test whether the secretion of the ER-Golgi network
is generally affected by necroptosis. Surprisingly, we detected
an increased release of signal proteins at 3 h of necroptosis
treatment (Figure 2E; Figure S2G), while intracellular levels ofCell Reports 30, 1260–1270, January 28, 2020 1261
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Figure 1. Supernatant Analysis of Cells Undergoing TNF-Induced Apoptosis and Necroptosis
(A) Schematic workflow of supernatant processing.
(B and C) Immunoblot of U937 cells treated with DMSO, TNF (30 ng/mL), and SM (birinapant, 250 nM) to induce apoptosis or with TNF, SM, and IDN-6556
(IDN-6556, 10 mM) to induce necroptosis for 1–7 h and blotted for the apoptotic markers cleaved caspase-8 and caspase-3 (B) and the necroptotic marker
phosphorylated MLKL (C) and the loading control GAPDH.
(D) Cell death analysis by flow cytometry of propidium iodide-positive cells, which were treated as indicated over a time course of 1–7 h (±SEM, n = 3 or 4).
(E) Number of all proteins quantified in the supernatant of cells treated as indicated in (D).
(F) Number of significantly changing proteins in supernatants of cells treated as indicated (Student’s t test: false discovery rate [FDR] = 0.05).the same proteins were unaffected (Figure S2H). Proteins that
are unconventionally secreted (assigned to the keyword
annotation ‘‘Secreted’’, excluding signal proteins) were not
changed in the supernatant of necroptotic cells (Figure 2E).
The release of conventionally released proteins at 3 h of
stimulation was most strongly inhibited in necroptotic cells by
brefeldin A treatment (Figure 2F), which leads to disruption of
the Golgi apparatus. This indicates that the ER-Golgi secretory
pathway is activated at early stages of necroptosis.
However, at 5 (Figures S2I and S2J) and 7 h of stimulation
(Figure 2G) we detected fewer signal proteins in supernatants1262 Cell Reports 30, 1260–1270, January 28, 2020of necroptotic cells compared with the control treated cells,
while intracellular levels were again unaffected (Figure S2K).
This corresponds to the missing impact of brefeldin A on
the signal protein level in supernatants of necroptotic
cells treated for 7 h (Figure 2H). To determine whether degrada-
tion of signal proteins occurs because of an increased release of
proteases at later stages of necroptosis, we analyzed semi-
tryptic peptides of those proteins. Semi-tryptic peptides are
generated by proteolytic processing prior to the proteomic
workflow. In necroptotic supernatants at 7 h of necroptosis in-
duction semi-tryptic peptides of signal proteins are slightly
Figure 2. The Release of Conventionally
Secreted Cytokines Is Reduced in Necrop-
totic Cells
(A–D) Graphs show the log2 intensity of CCL2 and
IL8 in supernatants of U937 cells (A and B) and
CCL24 and IL8 in supernatants of primary macro-
phages (C and D) measured using mass spectrom-
etry. Cells were either left untreated (black squares)
or treated with TNF (purple squares), TNF and SM
(green squares), or TNF, SM, and IDN-6556 (yellow
squares) over a time course of 1–7 h (for U937 cells)
and2–5h (forprimarymacrophages) (±SEM,n=3or
4). Full squares represent two or more valid values
for the data point. Asterisks show significant
changes (Student’s t test: FDR = 0.05).
(E and G) Swarm plot showing log2 fold change of
all proteins (dark gray) and proteins assigned to
the keyword annotation ‘‘Secreted’’ (all proteins
annotated to the keyword annotation ‘‘Signal’’
were excluded, light gray, 1D annotation, not
significant [n.s.], E, p = 1.83 104, G) and ‘‘Signal’’
(gray, p = 2.1 3 106, E, p = 2.8 3 1021, G)
released by necroptotic cells compared with the
DMSO control at 3 h (E) and 7 h (G) of treatment.
Taking the antilogarithm, we obtain fold changes
of the mean protein distributions (x for fold). Fold
changes above 0 represent enrichment and fold
changes below 0 represent de-enrichment.
(F and H) Swarm plot showing log2 fold change of
as ‘‘Signal’’ annotated proteins of U937 cells
treated with brefeldin A (BFA; 5 mg/mL) and DMSO
(black; p = 1.1 3 1027, F, p = 1.9 3 108, H), TNF
(purple; p = 1.5 3 1036, F, n.s., H), TNF and SM
(green; p = 5.8 3 1026, F, n.s., H), or TNF, SM,
and IDN-6556 (yellow; p = 1.8 3 1035, F, n.s., H)
compared with the same treatments without bre-
feldin A.increased compared with the same peptides in necroptotic su-
pernatants at 3 h of stimulation (Figure S2L). However, no
semi-tryptic peptide of the conventionally released cytokines
CCL2, IL8, and GRN could be detected. Necroptotic superna-
tants contained primarily semi-tryptic peptides of other proteins
than signal proteins (Figure S2L), suggesting that the reduction
of conventionally released proteins in supernatants of late-stage
necroptotic cells is not only due to increased proteolytic pro-
cessing. This indicates that the ER-Golgi secretory pathway is in-
hibited at later stages of necroptosis.
Although the inhibition of the ER-Golgi pathway at later stages
of necroptosis prevents the release of conventionally released
cytokines, TNF-induced cytokines CCL2 and IL8 levels wereCell Repoalready reduced at 3 h of stimulation
compared with TNF treatment alone. To
test whether CCL2 is transcribed in
response to TNF during necroptosis, we
measured its mRNA levels and found a
strong reduction compared with TNF-
only treated cells after 3 and 7 h of stimu-
lation (Figure S2M). The expression of
other TNF-induced genes in U937 cells
was also compromised. Of six proteinsstrongly upregulated in response to TNF treatment, we only
found SOD2 being upregulated during necroptosis (Figure S2N).
SQSTM1, NFKB2, ICAM1, PLAU, and JUND, which are all prom-
inent targets of TNF, were not induced during necroptosis.
Receptor SheddingOccurs in Necroptotic andApoptotic
Cells
Comparing proteins released by necroptotic supernatants and
apoptotic cells, we identified several proteins assigned to the
keyword annotations ‘‘Receptor’’ as most enriched in both
supernatants (Figures 3A–3C; Figure S3A; Table S2). This is
unlikely to be a consequence of passive protein release
caused by membrane damage, as necroptosis and apoptosisrts 30, 1260–1270, January 28, 2020 1263
Figure 3. Necroptosis and Apoptosis Induce Receptor Shedding Mediated by ADAMs
(A) Scatterplot plotting the log2 fold change of proteins released by necroptotic cells compared with the DMSO control against the fold change of proteins
released by apoptotic cells compared with the DMSO control (3 h of treatment). Proteins assigned to the keyword annotation ‘‘Receptor’’ (blue), ten most en-
riched receptors in apoptotic supernatants (dark blue, italics), and most significant receptors in necroptotic supernatants (dark blue, underlined).
(B) Swarm plot showing log2 fold change of all proteins (gray) and proteins assigned to the keyword annotation ‘‘Receptor’’ (blue; p = 2.6 3 10
6) released by
apoptotic cells compared with the DMSO control at 3 h of treatment.
(C) Swarm plot showing log2 fold change of all proteins (gray) and ‘‘Receptor’’ proteins (blue; p = 1.3 3 10
7) released by necroptotic cells compared with the
DMSO control at 3 h of treatment.
(D) Swarm plot showing log2 fold change of all proteins (gray), receptors (blue; n.s.), and significantly upregulated receptors in the supernatant of necroptotic cells
(dark blue) present in extracellular vesicles of necroptotic cells compared with the DMSO control at 3 h of treatment.
(E and F)Matching of detected peptides bymass spectrometry to corresponding proteins using R shows peptide fold changes (log2) in the supernatant (E) and the
cellular proteome (F) of necroptotic U937 cells at 3 h of stimulation compared with DMSO-treated control cells. Selected proteins are the four most enriched
receptors in the supernatant of necroptotic U937 cells compared with the DMSO control. Values are averages of n = 4.
(G) Swarm plot showing log2 fold change of all proteins (gray), receptors (blue; p = 6.8 3 10
13), and significantly upregulated receptors in the supernatant of
necroptotic cells (dark blue) present in supernatants of cells treated with TNF, SM, and IDN-6556 and the ADAM inhibitor GW280264X compared with cells
treated with TNF, SM, and IDN-6556 for 3 h.
(H) Swarm plot showing log2 fold change of all proteins (gray), receptors (blue; p = 3.0 3 10
3, FDR = 0.1), and significantly upregulated receptors in the su-
pernatant of necroptotic cells (dark blue) present in supernatants of cells deficient for RIPK3 treated with TNF, SM, and IDN-6556 compared with wild-type cells
treated the same for 3 h.
(I) Swarm plot showing log2 fold change of all proteins (gray), receptors (blue; p = 0.001), and significantly upregulated receptors in the supernatant of necroptotic
cells (dark blue) present in supernatants of cells treated with TNF, SM, IDN-6556, and the RIPK1 inhibitor necrostatin-1 (Nec-1) compared with cells treated with
TNF, SM, and IDN-6556 for 3 h.
(J) Swarm plot showing log2 fold change of all proteins (gray), receptors (blue; p = 1.4 3 10
6), and the ten most enriched receptors in the supernatants of
apoptotic cells (dark blue) present in supernatants of cells treated with TNF, SM, and the ADAM inhibitor GW280264X compared with cells treated with TNF and
SM for 3 h.
(legend continued on next page)
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induction at 3 h precedes membrane permeabilization (Fig-
ure 1D). To test whether the detected receptors are instead
released via exocytosis, we purified extracellular vesicles us-
ing serial centrifugation (STAR Methods). Proteomic analysis,
however, showed no enrichment for receptors in extracellular
vesicles of necroptotic and apoptotic cells compared with the
control (Figure 3D; Figure S3B). Next, we sought to determine
whether ectodomains are cleaved off the receptors and
therefore enriched in necroptotic supernatants. Indeed, pep-
tides derived from receptor ectodomains were preferentially
released into the supernatant, whereas transmembrane or
cytoplasmic domain peptides were either not detected or
not enriched compared with supernatants of DMSO-treated
cells (Figure 3E; Figure S3C). These cytoplasmic regions
were readily detected when measuring the cellular proteome
(Figure 3F; Figure S3D). A recent study showed that shedding
during necroptosis contributes to inflammation and cell
death in an MLKL-dependent manner (Cai et al., 2016). We
show here that shedding also occurs to a lesser degree in
apoptotic cells. Western blot analysis on the cell lysates did
not detect phosphorylated/active MLKL at any time points
during apoptosis induction, ruling out the possibility that nec-
roptotic cells were present during apoptotic stimulation
(Figure S4E).
Next, we tested whether this shedding is mediated via A
disintegrin and metalloproteinase 10 (ADAM10) and 17, which
are members of the disintegrins and metalloproteinase family
(Cai et al., 2016). Indeed, specific inhibition of ADAM17 and
ADAM10 with GW280264X reduced the release of receptors
in necroptotic as well as apoptotic cells, while the release of
proteins without receptor annotations remained unchanged
(Figures 3G and 3J).
The lack of motif specificity for ADAM substrates complicates
substrate prediction (Gooz, 2010), and we wished to investigate
if there was a relationship between receptor abundance and re-
ceptor shedding. From the proteomic analysis of receptor levels
in untreated cells, we conclude that the expression level itself
has no impact on shedding (Figure S3F). Furthermore, the
enrichment of shed receptors in the supernatant of necroptotic
cells corresponded with their de-enrichment in these cells at
3 h after induction (Figure S3G).
Necroptosis-induced shedding was strongly inhibited in U937
cells deficient for RIPK3, the key activator of MLKL, or in U937
cells additionally treated with the RIPK1 inhibitor necrostatin-1
(Nec-1), where activation of MLKL cannot occur (Figures 3H
and 3I; Figures S3H and S3I). In contrast to shedding during nec-
roptosis, apoptosis-induced shedding was not prevented in
RIPK3-deficient U937 cells or by addition of the RIPK1 inhibitor
Nec-1 (Figures 3K and 3L). This indicates that TNF-induced
shedding can be completely prevented only by blocking both
caspase activation and the necroptotic pathway. Hence, we
conclude that the shedding of receptors occurs during TNF-(K) Swarm plot showing log2 fold change of all proteins (gray), receptors (blue; n.
cells deficient for RIPK3 treated with TNF and SM compared with wild-type cells
(L) Swarm plot showing log2 fold change of all proteins (gray), receptors (blue; p =
in supernatants of cells treated with TNF, SM, and the RIPK1 inhibitor necrostati
(M) Scheme of receptor shedding downstream of apoptosis and necroptosis indinduced cell death and is not only restricted to necroptosis
(Figure 3M).
Apoptotic Cells Exclusively Release Histones while
Necroptotic Cells Release Lysosomal Proteins
We observed the release of apoptotic- and necroptotic-specific
proteins. A group of proteins annotated as nucleosome compo-
nents were most strongly enriched in supernatants of apoptotic
cells (Figures 4A–4C; Figures S4A–S4C) at 3 h when DNA frag-
mentation and chromatin condensation were detected (Figures
S4D and S4E). This was not the case in necroptosis, in which
nucleosomes were de-enriched (Figure 4A; Figure S4F).
Necroptotic cells showed an increased release of lysosomal
proteins after 3 h of necroptosis stimulation (Figures 4A and
4D; Figure S4G; Table S2), which was not evident during
apoptosis. The release of lysosomal components was strongly
reduced by the RIPK1 inhibitor Nec-1 and even more so in
RIPK3-deficient U937 cells, suggesting a necroptosis-specific
release pathway (Figures S4H and S4I).
Because many lysosomal proteins require cleavage for full
activation, we examined whether the released lysosomal com-
ponents are present in mature (cleaved) or premature (un-
cleaved) forms. Matching the peptide sequences to their pro-
teins revealed that the majority were located within the mature
forms of proteins released by necroptotic cells (Figure S4J).
Consistently, we detected an increase of mature cathepsin B
and cathepsin D in supernatants of necroptotic cells compared
with DMSO-treated cells by immunoblotting (Figure S4K).
Furthermore, we observed a significant increase of semi-tryptic
peptides with comparable intensities to tryptic peptides of the
same proteins in the supernatants of necroptotic cells (Fig-
ure S4L). Their near doubling (at 7 h) proves a dramatic increase
of enzymatic activity in the supernatants of necroptotic cells.
This is less likely due to increased ADAM activity, as they are
active before and at 3 h of necroptosis induction. The numbers
of all peptides identified across treatments did not significantly
change (Figure S4M).
Membrane Permeabilization during Necroptosis
Induces Lysosomal Exocytosis
Several studies have implicated the lysosomal machinery in nec-
roptosis. The bursting of lysosomeswithin cells during necropto-
sis that preceded membrane permeabilization has been
described (Vanden Berghe et al., 2010), and a role for MLKL in
endosomal trafficking and increased vesicle formation has
been reported (Yoon et al., 2017). Taking these studies into
consideration, we asked whether lysosomal proteins were
released via extracellular vesicles during exocytosis. Principal-
component analysis revealed a clear separation of extracellular
vesicle proteomes derived from apoptotic and necroptotic
cells (Figure S4N). Consistent with previous reports, levels of
MLKL and ESCRT proteins, which are involved in extracellulars.), and the ten most enriched receptors (dark blue) present in supernatants of
treated the same for 3 h.
2.03 103, FDR = 0.1), and the tenmost enriched receptors (dark blue) present
n-1 (Nec-1) compared with cells treated with TNF and SM for 3 hours.
uction.
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Figure 4. Lysosomal Proteins Are Released by Necroptotic Cells via Lysosomal Exocytosis
(A) Scatterplot plotting the log2 fold change of proteins released by necroptotic cells compared with the DMSO control against the fold change of proteins
released by apoptotic cells compared with the DMSO control (3 h of treatment; ‘‘Nucleosome’’ [green], ‘‘Lysosome’’ [red]).
(B) Swarm plot showing log2 fold change of all proteins (gray) and proteins assigned to the GOCC annotation ‘‘Nucleosome’’ (green; p = 1.23 10
5) released by
apoptotic cells compared with the DMSO control at 3 h of treatment.
(C and D) 1D annotation enrichment analysis of all proteins in the supernatant of apoptotic (C) and necroptotic (D) U937 cells treated for 3 h compared with the
DMSO-treated control cells. Annotations including ‘‘Nucleosome’’ (C) and ‘‘Lysosome’’ (D) were selected and ranked from higher score to lower score (Benjamini-
Hochberg FDR = 0.02) (STAR Methods). KEGG, Kyoto Encyclopedia of Genes and Genomes; GOCC, Gene Ontology cellular components; GOMF, Gene
Ontology molecular function.
(E) Swarm plot showing log2 fold change of all proteins (gray) and proteins assigned to the annotation ‘‘Calcium/phospholipid binding’’ (keyword, yellow), the
‘‘ESCRTIII complex’’ (GOCC, blue), and ‘‘SNARE complex’’ (GOCC, green) present in extracellular vesicles of necroptotic cells compared with the DMSO control
(legend continued on next page)
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vesicle formation and removal of MLKL from the plasma mem-
brane, were increased in extracellular vesicles derived from
necroptotic cells compared with control or apoptotic cells after
3 h of stimulation (Yoon et al., 2017; Gong et al., 2017) (Figures
4E and 4F; Figure S4O).
Interestingly, we observed a significant enrichment of lyso-
somal components in extracellular vesicles of necroptotic cells
(Figures 4F and 4G; Figure S4O). Luminal lysosomal proteins
were preferentially present in total supernatants, whereas
membrane-bound ones were found mainly in purified extracel-
lular vesicles (Figures 4H and 4G). Distribution of lysosomal
membrane and lysosomal luminal proteins differed significantly
(p < 0.0001). In classical endosomal exocytosis, luminal and
membrane lysosomal proteins would be co-released in extra-
cellular vesicles, which is not the case here.
An alternative process, termed lysosomal exocytosis, which
occurs in response to plasma membrane permeabilization, for
example, through ionomycin treatment or mechanical stress,
has also been described in TNF-treated L929 cells, presumably
to repair plasma membranes (Andrews, 2002; Reddy et al.,
2001; Ono et al., 2001). In that process, the lysosomal mem-
brane fuses with the plasma membrane, releasing its cargo
into the extracellular space. This corresponds with our obser-
vation that luminal lysosomal proteins are enriched in the super-
natant, and membrane lysosomal proteins are enriched in
extracellular vesicles that also contain plasma membrane.
Also the enrichment of calcium/phospholipid-binding and
SNARE (SNAP receptor) proteins, which play an important
role in vesicle fusion in response to increased intracellular
free calcium upon membrane permeabilization, fits the model
of lysosomal exocytosis. (Rao et al., 2004; Shen et al., 2016)
(Figures 4E, 4F, and 4K; Figure S4O).
To determine the role of lysosomal exocytosis in the release
of lysosomal components, we inhibited lysosomal exocytosis
using vacuolin, which leads to homotypic fusion of endosomes
and lysosomes. It blocks calcium-dependent exocytosis in a
cell type-dependent manner (Cerny et al., 2004; Lu et al., 2014;
Shaik et al., 2009). Treatment of necroptotic cells with vacuolin
partially inhibited the release of lysosomal components in the to-
tal supernatant (Figures 4I and 4J).at 3 h of treatment. The p value (log10) of the 1D annotation enrichment for ‘‘Calc
and for ‘‘SNARE complex’’ is 1.7 3 109.
(F) 1D annotation enrichment analysis of all proteins of extracellular vesicles in th
6556 compared with the DMSO-treated control cells. Annotations are ranked fro
(G) Swarm plot showing log2 fold change of all proteins (gray) and proteins assigne
(GOCC, nude), and ‘‘Lysosomal membrane’’ (GOCC, pink) in extracellular vesicle
p value (log10) of the 1D annotation enrichment for ‘‘Lysosome’’ is 3.83 1023, fo
is 2.7 3 1029.
(H) Swarm plot showing log2 fold change of the same annotation groups as in (G
control at 3 h of treatment. The p value (log10) of the 1D annotation enrichment
‘‘Lysosomal membrane’’ is 1.0 3 103.
(I) Swarm plot showing log2 fold change of all proteins (gray) and lysosomal protein
lysosomal exocytosis inhibitor vacuolin compared with cells treated with TNF, SM
‘‘Lysosome’’ is 9.8 3 1012 and for ‘‘Lysosomal lumen’’ is 3.7 3 1010.
(J) 1D annotation enrichment analysis of all proteins in the supernatant of ne
compared with the same treatment without vacuolin. Annotations containing ‘‘
Hochberg FDR = 0.02).
(K) Scheme of lysosomal exocytosis and formation of extracellular vesicle as resDISCUSSION
Chronic inflammatory TNF-induced cell death is a major contrib-
utor to a range of inflammatory diseases, as dying cells expose
immunogenic proteins normally found within the cell. Our prote-
omic approach provided a comprehensive and unbiased view
on proteins released by apoptotic and necroptotic cells. As
expected, many proteins were statistically significantly changed
in supernatants of apoptotic cells compared with control. This
was even more pronounced in necroptosis, particularly at
later time points.
The release of pro-inflammatory cytokines contributes to
the immunogenicity of cell death pathways. Whereas conven-
tionally released cytokines were generally reduced in superna-
tants of necroptotic cells, non-conventionally released cytokines
were primarily unchanged or increased compared with TNF
alone or apoptosis. Plasma membrane permeabilization facili-
tates the unconventional release of cytokines. The reduction of
conventionally released cytokines is due to the inhibition of
the ER-Golgi trafficking pathway at later stages of necroptosis
and the early plasma membrane permeabilization, which is
most likely the reason for compromised transcription and
expression of TNF-induced proteins. These findings do not
conflict with the results of Orozco et al. (2019) regarding contin-
uous cytokine mRNA translation despite plasma membrane
permeabilization during necroptosis, because the cytokine pro-
duction of stimulated living cells is expected to exceed that of
necroptotic cells.
Other immunogenic proteins were differentially released by
apoptotic and necroptotic cells, such as histones, which were
increased only in supernatants of apoptotic cells. They are linked
to diseases like lupus (Chen et al., 2014; Radic et al., 2004),
chronic obstructive pulmonary disease (COPD), cerebral stroke,
and sepsis. Conversely, HMGB1, a highly inflammatory mole-
cule, was increased in the supernatants of necroptotic cells, as
previously described (Magna and Pisetsky, 2014).
Besides the detection of proteins with known intercellular
functions, our study provides insights into intracellular mecha-
nisms that occur during TNF-induced cell death and that may
also contribute to inflammation. For example, we observed anium/phospholipid binding’’ is 5.33 109, for ‘‘ESCRTIII complex’’ is 2.93 105,
e supernatant of necroptotic U937 cells treated for 3 h with TNF, SM, and IDN-
m higher score to lower score (Benjamini-Hochberg FDR = 0.02).
d to the keyword annotations ‘‘Lysosome’’ (keywords, red), ‘‘Lysosomal lumen’’
s of necroptotic cells compared with the DMSO control at 3 h of treatment. The
r ‘‘Lysosomal lumen’’ is 9.23 103 (FDR = 0.1), and for ‘‘Lysosomal membrane’’
) released into the supernatant of necroptotic cells compared with the DMSO
for ‘‘Lysosome’’ is 1.6 3 1010, for ‘‘Lysosomal lumen’’ is 2.4 3 105, and for
s (red) present in supernatants of cells treatedwith TNF, SM, IDN-6556, and the
, and IDN-6556 for 3 h. The p value (log10) of the 1D annotation enrichment for
croptotic U937 cells treated for 3 h with TNF, SM, IDN-6556, and vacuolin
Lysosome’’ are selected and ranked from higher to lower score (Benjamini-
ponse to plasma membrane permeabilization during necroptosis.
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enrichment of receptor ectodomains in supernatants of necrop-
totic and apoptotic cells due to ADAM-mediated shedding. This
is a physiologically important process: the cleavage of cell
adhesion proteins promotes detachment of dying cells from
surrounding tissue; receptor cleavage abrogates signal trans-
duction into the cell as well as between cells by the generation
of decoy receptors cleavage (Blaydon et al., 2011; Jones et al.,
2016). Together, this switches signaling within dying cells to
signaling between cells by the release of autocrine and paracrine
signals. Shedding was already reported to be activated during
necroptosis (Cai et al., 2016). Our data provide a catalog of
proteins affected and demonstrate that it occurs at later stages
of TNF-induced cell death and can be prevented only by
inhibiting both apoptotic and necroptotic executioners. Further
studies should delineate the intercellular activities of the distinct
signals released by the different forms of cell death on neigh-
boring cells.
A second unexpected group of proteins released by necrop-
totic cells belong to lysosomes. We conclude that this is caused
by lysosomal fusion to the plasmamembrane, a mechanism that
results in the release of lysosomal cargo into the supernatant in
response to membrane permeabilization, described as lyso-
somal exocytosis.
Lysosomal exocytosis was originally described as a plasma
membrane repair mechanism in response to Ca2+ influx (Reddy
et al., 2001). A study on the infection of pathogens with bacterial
type III secretion system confirmed this role (Roy et al., 2004).
During necroptosis the ESCRT machinery removes MLKL from
the plasma membrane to prevent membrane permeabilization
(Yoon et al., 2017; Gong et al., 2017). We speculate that lyso-
somal exocytosis is an additional and very last resort to protect
the cell from death (Ono et al., 2001). Lysosomal exocytosis was
also investigated as a defense mechanism to remove intracel-
lular pathogens (Miao et al., 2015), but the effect of lysosomal
enzymes on pathogens in the extracellular regions has not
been studied in detail. Many lysosomal enzymes work best at
acidic pH but may still retain some enzymatic activity in the
extracellular space, which is sufficient to degrade the extracel-
lular matrix (Fonovic and Turk, 2014). This is consistent with
our observation of increased semi-tryptic peptides in superna-
tants of necroptotic cells, which indicates increased proteolytic
activity. These lysosomal enzymes may also affect cells in
close proximity. Whether lysosomal exocytosis following nec-
roptosis induction is just a consequence of cell membrane per-
meabilization or a last chance to rescue dying cells, and whether
it significantly affects the environment, such as pathogens or
neighboring cells, are exciting questions for future studies.
In conclusion, our study provides in-depth, quantitative, and
dynamic catalogs of proteins differentially and commonly
released during apoptotic and necroptotic cell death. This offers
a solid basis for investigating the complexity of biological pro-
cesses that are either incidental or regulated, harmful or func-
tional during apoptosis and necroptosis. Our results demon-
strate that an unexpectedly wide range of different proteins are
released. Only some of these contribute directly to inflammation,
whereas others are more likely to act in more complex ways that
still need to be elucidated in detail in these very different modes
of cell death.1268 Cell Reports 30, 1260–1270, January 28, 2020STAR+METHODS
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Human primary macrophages made
out of buffy coats
Blood donation to the Red cross N/A
Oligonucleotides
sgRNA 1 against RIPK3:
gaattcgtgctgcgcctaga
Tanzer et al., 2017 Metabion




lentiCRISPR v2 Transomics TELA1002
psPAX2 http://addgene.org/12260 Addgene #122260
pMD2.G http://addgene.org/12259 Addgene #122259
Software and Algorithms
MaxQuant Cox and Mann, 2008, Version 1.5.0.38 https://www.biochem.mpg.de/5111795/maxquant
Perseus Tyanova et al., 2016, Version 1.5.3.0 https://www.biochem.mpg.de/5111810/perseus
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REAGENT or RESOURCE SOURCE IDENTIFIER
XCalibur Thermo Scientific https://www.thermofisher.com/order/catalog/
product/OPTON-30487
Prism Graphpad N/A https://www.graphpad.com/scientific-
software/prism/
Instant Clue Nolte et al., 2018 http://www.instantclue.uni-koeln.de/
FlowJo N/A https://www.flowjo.com/
R N/A https://www.r-project.org/








PRIDE Jones et al., 2008 https://www.ebi.ac.uk/pride/archive/LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources should be directed to and will be fulfilled by the Lead Contact, Felix Meissner
(meissner@biochem.mpg.de). This study did not generate new unique materials and reagents.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Experiments described in this study are performedwith the U937 cell line and human primarymacrophages. U937were purchased at
ATCC and cultured in RPMI supplemented with 10% FCS and Pen/Step. Human primary macrophages were generated by isolating
PBMCs from buffy coats (generated from blood donations) using Histopaque-1077 (Sigma-Aldrich, 10771). Monocytes were isolated
using a monocyte isolation kit (Miltenyi Biotec, 130-091-153), plated and 50 nM GM-CSF (ImmunoTools, 21173121) was added.
Cells were left for 7 days to induce macrophage differentiation. All cells were stimulated and kept for the entire treatment duration
in serum- and phenol-red free media (Thermo Fisher Scientific, 11835063).
METHOD DETAILS
Sample preparation for proteomic analysis and ELISA of supernatants
1.53 106 U937 cells or full 24 wells of primary humanmacrophages were treated with TNF (30 ng/ml) and the IAP inhibitor, birinapant
(SM, 250 nM) (Compound A (2 mM) for human primary macrophages) to induce apoptosis or TNF and birinapant (SM, 250 nM)
(Compound A (2 mM) for human primary macrophages) and the caspase inhibitor IDUN-6556 (IDN-6556/emricasan, 10 mM) to induce
necroptosis, GW280264X (10 mM, pretreatment for 60 minutes before apoptosis and necroptosis induction), necrostatin-1 (Nec-1,
50 mM), vacuolin-1 (vacuolin, 10 mM) and brefeldin A (BFA, 3 mg/ml, 20 minutes before apoptosis and necroptosis induction).
Control cells were treated with DMSO, TNF, birinapant and IDUN-6556 alone. For ELISA supernatants were taken and processed
according to the manufacturer’s instruction. For proteomic analysis supernatants were spun for 5 minutes at 500 x g to remove cells
and filtered through 0.22 mm filters to remove cell debris. 8 M urea in 40 mM HEPES was added to bring the sample to a final con-
centration of 2.7 M urea, which was subsequently sonicated (Biorupter) for 20 minutes. Proteins were reduced by the addition of
10 mM DTT and incubated for 30 minutes at room temperature. Proteins were alkylated by the addition of 55 mM iodoacetamide
and incubated for 20 minutes at room temperature in the dark. 100 mM Thiourea was added before the addition of 1 mg lysC
and trypsin and digested over night at room temperature. Enzyme activity was stopped by the addition of 2% ACN and 0.6%
TFA and proteins were cleaned up on C18 StageTips (Frauenstein and Meissner, 2018).
Preparation of extracellular vesicles
12 3 106 U937 cells were treated for three hours with TNF and birinapant or TNF and birinapant and IDUN-6556 or with DMSO
alone as a control. Cells were spun for 5 minutes at 500 x g. Supernatants were taken and spun again for 30 minutes at
10,000 x g. Supernatants were taken again and spun for 60 minutes at 100,000 x g to obtain extracellular vesicles. The pellets con-
taining extracellular vesicles were washed with ice cold PBS and again centrifuged for 60 minutes at 100,000 x g. Extracellular ves-
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with lysC (1 mg/sample) before 1:4 dilution with 50 mM ammonium bicarbonate and the addition of trypsin (1 mg/sample). Trypsin and
lysC digestion occurred over night at room temperature and peptides were cleaned up by C18 stage tipping.
Western blotting
Two million cells were stimulated, washed in PBS and lysed in buffer (1% IGEPAL, 10% Glycerol, 2 mM EDTA, 50 mM Tris pH 7.5,
150mMNaCl) supplemented with phosphatase- (Sigma-Aldrich, 4906845001) and protease inhibitors (Sigma-Aldrich, 4693159001).
Lysates were kept on ice for 20 minutes and centrifuged at 16,100 x g for 15 minutes before the addition of 6 x SDS sample loading
buffer (450 mM Tris-HCl, pH 8, 60% (v/v) glycerol, 12% (w/v) SDS, 0.02% (w/v) bromophenol blue, 600 mMDTT) to the supernatant,
followed by boiling and sonication. For immunoblotting of supernatants ten million cells were stimulated in serum-free media, spun
down and proteins in supernatants were precipitated with ice-cold Acetone (80%final concentration). The next day precipitates were
spun down for 30 minutes at full speed and washed twice in 80% Acetone before addition of 6 x SDS sample loading buffer, boiling
and sonication. Separation occurred on 12% Novex Tris-glycine gels (Thermo Fisher Scientific, XP00120BOX) and transferred
onto PVDF membranes (Merck Millipore, IPVH00010) or Nitrocellulose membranes (Amersham, 10600002). Membranes were
blocked in 5% milk and antibodies diluted in 2% BSA in PBST. Antibodies used for immunoblotting were as follows: anti-human
caspase-8 (MBL, M058-3), anti-cleaved human caspase-3 (Cell Signaling, 9661), anti-human phospho (S358) MLKL (Abcam,
ab187091), anti-human MLKL (Merck Millipore, MABC604), anti-GAPDH (Cell Signaling Technology, 8884s), anti-CATHEPSIN B
(Calbiochem, IM27L) and anti-CATHEPSIN D (Abcam, ab75825).
Cell death analysis
13 105 U937 cells and human primarymacrophages were plated in 24well plates and treated with TNF (30 ng/ml), IDN-6556 (10 mM),
necrostatin-1 (Nec-1, 50 mM), birinapant (SM, 250 nM) for U937 and Compound A (SM, 2 mM) for human primary macrophages.
Cell death was measured by propidium iodide incorporation using flow cytometry (FACS Attune NxT, BD FACS Aria III) and analyzed
using Graphpad Prism.
DNA laddering assay
DNA laddering assay was performed as described previously with some changes (Kralj et al., 2003). After stimulation 2 3 106 cells
were washedwith PBS and lysed in 200 ml of lysis buffer (1%NP-40 in 20mMEDTA, 50mMTris-HCl, pH 7.5), centrifuged at 3000 rpm
for 5 min and supernatants were collected. SDS (1%) and RNase A (5 mg/ml) were added for 1 h at 56C and proteinase K (2.5 mg/ml)
was added for 1 h at 37C. Afterward, ½ volume of ammonium acetate (stock 10 M), 2 volume of ice cold ethanol were added,
followed by incubation overnight at 80C. Samples were centrifuged the next day (14000 rpm) for 40 min at 4C. Pellets were
washed with 70% ethanol and dissolved in 20 ml of water. Equal amounts of DNA were loaded for each condition on a 2% agarose
gel.
qPCR
RNAwas isolated from23 106 cells with the RNeasy PlusMini kit (QIAGEN) and reversely transcribedwith SuperScript III (Invitrogen).
cDNA was amplified with SYBR Green on a Biorad C1000 Thermal Cycler. Primers used were CCL2 (CCCCAGTCACCTGCTGTTAT)
andGAPDH (GTCTCCTCTGACTTCAACAGCG). Fold induction compared to untreated controls was calculated by the delta-delta CT
method.
Chromatography and mass spectrometry
Samples were loaded onto 50-cm columns packed in-house with C18 1.9 mM ReproSil particles (Dr Maisch GmbH), with an EASY-
nLC 1000 system (Thermo Fisher Scientific) coupled to the MS (Q Exactive HF, Thermo Fisher Scientific). A homemade column oven
maintained column temperature at 60C. Peptides were introduced onto the column with buffer A (0.1% Formic acid) and eluted with
a 107.3-min gradient of 5 to 25% of buffer B (60% ACN, 0.1% Formic acid), both at a flow rate of 300 nl/min.
A data-dependent acquisition (TopN) MS method was used in which one full scan (300 to 1650 m/z, R = 60,000 at 200 m/z) at a
target of 33 106 ions was first performed, followed by 15 data-dependent MS/MS scans with higher energy collisional dissociation
[target 105 ions, max ion fill time 55 ms, isolation window 1.4m/z, normalized collision energy 27%, R = 15,000 at 200m/z]. Dynamic
exclusion of 20 s and apex trigger (4 to 7 s) was enabled.
QUANTIFICATION AND STATISTICAL ANALYSIS
MS raw files were processed by the MaxQuant software version 1.5.0.38 (Cox and Mann, 2008) and fragments lists were searched
against the human Uniprot Reference Proteome without isoforms (August 2015) by the Andromeda search engine (Cox et al., 2011)
with cysteine carbamidomethylation as a fixed modification and N-terminal acetylation and methionine oxidations as variable
modifications. We set the false discovery rate (FDR) to 0.01 at the peptide and protein levels and specified a minimum length of 7
amino acids for peptides. Enzyme specificity was set as C-terminal to Arginine and Lysine as expected using Trypsin and LysC
as proteases and set as semi-tryptic for semi-tryptic peptide analysis, and a maximum of two missed cleavages.e4 Cell Reports 30, 1260–1270.e1–e5, January 28, 2020
All bioinformatics analyzes were done with the Perseus software (version 1.5.3.0) (Tyanova et al., 2016) of the MaxQuant compu-
tational platform. Quantified proteins are filtered for at least 75% of valid values among three or four biological replicates in at least
one condition. Missing values were imputed and significantly up- or downregulated proteins were determined by multiple-sample
test (FDR = 0.05) and Student’s t test (two-sided), (FDR = 0.05). n represents replicates of the same cell line stimulated separately.
Further statistical details of experiments can be found in the figure legends.
The 1D annotation enrichment analysis detects whether expression values of proteins belonging to an enrichment term (here we
used: keywords, GOCC, GOMF, GOBP and KEGG name) show a systematic enrichment or de-enrichment compared to the distri-
bution of all expression values (Cox and Mann, 2012).
Swarm plots were created using the software Instant Clue (Nolte et al., 2018).
DATA AND CODE AVAILABILITY
TheMS-based proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository and are
available via ProteomeXchange with identifier (PXD014966) (Jones et al., 2008).Cell Reports 30, 1260–1270.e1–e5, January 28, 2020 e5
